Literature DB >> 34188479

Impact of Physical Inactivity on the Risk of Disability and Hospitalization in Older Patients with Advanced Lung Cancer.

Yusuke Yonenaga1, Tateaki Naito2, Taro Okayama1, Midori Kitagawa1, Noriko Mitsuhashi1, Takeshi Ishii1, Hiroshi Fuseya1, Toshimi Inano3, Ayumu Morikawa4, Miwa Sugiyama4, Keita Mori5, Akifumi Notsu5, Takanori Kawabata5, Akira Ono2, Hirotsugu Kenmotsu2, Haruyasu Murakami2, Akira Tanuma6, Toshiaki Takahashi2.   

Abstract

PURPOSE: This prospective observational study aimed to explore the influence of physical inactivity during initial chemotherapy on the risk of disability and hospitalization in later life among older patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients aged 70 or above who were scheduled to receive first-line chemotherapy for newly diagnosed advanced NSCLC were recruited for the study. An electronic pedometer was used to measure daily steps; based on the change rate (cutoff: -12.5%) from pretreatment to 12 ± 4 weeks after enrolment, patients were classified as active or inactive. The Barthel Index estimated activities of daily living. We compared disability-free survival time, mean cumulative functions of hospital stays, and medical costs, between the active and inactive groups.
RESULTS: Among the 29 patients enrolled, 21 were evaluable. Compared with active patients (n = 11), inactive patients (n = 10) showed shorter disability-free survival (6.4 vs 19.9 months, p < 0.05) and tended to have longer hospital stays (23.7 vs 6.3 days/person) and higher inpatient care cost (¥1.6 vs ¥0.3 million/person [US$16,000 vs US$3000/person]) during the first year.
CONCLUSION: Physical inactivity during initial chemotherapy may be a risk factor for developing disability and requiring hospitalization in later life for older patients with advanced NSCLC. Our findings may indicate the need for lifestyle interventions with multidisciplinary teams, which include physicians, nurses, and physiotherapists, for older patients with advanced lung cancer during an active cancer treatment. A large-sample-sized study is needed to validate our findings.
© 2021 Yonenaga et al.

Entities:  

Keywords:  disability-free survival; length of hospital stay; medical cost; non-small-cell lung cancer; older patients; physical activity

Year:  2021        PMID: 34188479      PMCID: PMC8232865          DOI: 10.2147/JMDH.S311225

Source DB:  PubMed          Journal:  J Multidiscip Healthc        ISSN: 1178-2390


  48 in total

1.  The use of uniaxial accelerometry for the assessment of physical-activity-related energy expenditure: a validation study against whole-body indirect calorimetry.

Authors:  Hideaki Kumahara; Yves Schutz; Makoto Ayabe; Mayumi Yoshioka; Yutaka Yoshitake; Munehiro Shindo; Kojiro Ishii; Hiroaki Tanaka
Journal:  Br J Nutr       Date:  2004-02       Impact factor: 3.718

2.  Actigraphy as an assessment of performance status in patients with advanced lung cancer.

Authors:  Daisuke Fujisawa; Jennifer S Temel; Joseph A Greer; Areej El-Jawahri; Lara Traeger; Jamie M Jacobs; Stacy Cutrono; William F Pirl
Journal:  Palliat Support Care       Date:  2019-10

Review 3.  Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine.

Authors:  R R Pate; M Pratt; S N Blair; W L Haskell; C A Macera; C Bouchard; D Buchner; W Ettinger; G W Heath; A C King
Journal:  JAMA       Date:  1995-02-01       Impact factor: 56.272

4.  Continuous Activity Monitoring During Concurrent Chemoradiotherapy.

Authors:  Nitin Ohri; Rafi Kabarriti; William R Bodner; Keyur J Mehta; Viswanathan Shankar; Balazs Halmos; Missak Haigentz; Bruce Rapkin; Chandan Guha; Shalom Kalnicki; Madhur Garg
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-12-25       Impact factor: 7.038

5.  Modified frailty index predicts postoperative outcomes in older gastrointestinal cancer patients.

Authors:  Sarah A Vermillion; Fang-Chi Hsu; Robert D Dorrell; Perry Shen; Clancy J Clark
Journal:  J Surg Oncol       Date:  2017-04-24       Impact factor: 3.454

6.  Low physical activity levels and functional decline in individuals with lung cancer.

Authors:  Catherine L Granger; Christine F McDonald; Louis Irving; Ross A Clark; Karla Gough; Andrew Murnane; Linda Mileshkin; Meinir Krishnasamy; Linda Denehy
Journal:  Lung Cancer       Date:  2013-11-26       Impact factor: 5.705

7.  Unplanned hospital readmissions after HeartMate II implantation: frequency, risk factors, and impact on resource use and survival.

Authors:  Nicholas G Smedira; Katherine J Hoercher; Brian Lima; Maria M Mountis; Randall C Starling; Lucy Thuita; Darlene M Schmuhl; Eugene H Blackstone
Journal:  JACC Heart Fail       Date:  2013-02-04       Impact factor: 12.035

8.  A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol.

Authors:  Satoru Miura; Tateaki Naito; Shuichi Mitsunaga; Katsuhiro Omae; Keita Mori; Toshimi Inano; Teiko Yamaguchi; Noriatsu Tatematsu; Taro Okayama; Ayumu Morikawa; Takako Mouri; Hisashi Tanaka; Madoka Kimura; Hisao Imai; Takuro Mizukami; Akira Imoto; Chihiro Kondoh; Shinsuke Shiotsu; Hiroyuki Okuyama; Makoto Ueno; Toshiaki Takahashi; Tetsuya Tsuji; Hideki Aragane; Akio Inui; Takashi Higashiguchi; Koichi Takayama
Journal:  BMC Cancer       Date:  2019-05-31       Impact factor: 4.430

Review 9.  Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?

Authors:  Massimo Lanza; Sara Pilotto; Alice Avancini; Giulia Sartori; Anastasios Gkountakos; Miriam Casali; Ilaria Trestini; Daniela Tregnago; Emilio Bria; Lee W Jones; Michele Milella
Journal:  Oncologist       Date:  2019-11-26

10.  Factors Influencing Physical Activity in Cancer Patients During Oncological Treatments: A Qualitative Study.

Authors:  Alice Avancini; Daniela Tregnago; Laura Rigatti; Giulia Sartori; Lin Yang; Ilaria Trestini; Clelia Bonaiuto; Michele Milella; Sara Pilotto; Massimo Lanza
Journal:  Integr Cancer Ther       Date:  2020 Jan-Dec       Impact factor: 3.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.